Hotelbuchung
Hotel Registration
Grußwort
Welcome address
Beteiligte Gesellschaften
Societies involved
DOG Information
DOG Information
Eröffnung des Kongresses
Opening Ceremony
Preise
Awards
Ablauf der Tagung 2003
General overview of congress
Lageplan der Räumlichkeiten
Map of Congress Center
Wissenschaftliche Themen
Scientific topics
Symposien
Symposia
Wissenschaftliches Programm
Scientific program
Posterpräsentationen
Poster Presentation
Kurse
Courses
Begleitende Veranstaltungen
Accompanying program
Arbeitssitzungen
Working sessions
Rahmenprogramm
Social program
Allgemeine Informationen
General Information
Autorenindex
Index of Authors
Industrieaussteller
Commercial exhibitors
Sponsoren
Sponsors
Impressum
DOG Homepage
Abstract
Abstract
Intraocular Pressure after Intravitreal Injection of Triamcinolone Acetonide
Kreissig I., Jonas J. B., Degenring R.
Department of Ophthalmology, Faculty of Clinical Medicine Mannheim of the University Heidelberg
Purpose: To investigate the intraocular pressure (IOP) response after intravitreal injections of triamcinolone acetonide as treatment of intraocular neovascular or edematous diseases.
Method: The prospective consecutive non-comparative interventional case-series study included 71 patients (75 eyes) with progressive exudative age-related macular degeneration (n=64 eyes) or diffuse diabetic macular edema (n=11 eyes), who received an intravitreal injection of 25 mg triamcinolone acetonide. Mean follow-up time was 6.86 ± 2.52 months (range, 3.1-14.47 months).
Results: Intraocular pressure increased significantly (P<0.001) from 15.43 ± 3.26 mm Hg preoperatively to a mean maximum of 23.38 ± 8.37 mm Hg (range, 13 64 mm Hg) postoperatively. An IOP rise to values higher than 21 mm Hg was observed in 39 (52%) eyes. Elevation of IOP occurred about two months after the injection. Preoperative predictive factor for the rise in IOP was younger age (p=0.013). It was statistically independent of refractive error, presence of diabetes mellitus, and indication for the injection. In all but one eye, IOP could be lowered to the normal range with topical medication, without development of glaucomatous optic nerve head changes. In the eyes with an elevation of IOP, IOP normalized about six months after the injection, without further medication. Eyes undergoing repeatedl